Sharemaestro company-news research for Vir Biotechnology Inc (VIR), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest VIR news and sentiment
Vir Biotechnology Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone39/100
→
Published 30-day score50/100
Latest source headline
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Business Wire · 07 Oct 2026 12:30
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
15 current stories are mapped specifically to VIR.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.017.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news15 company stories
98/100
Story agreement2/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.017 after freshness weightingSource breadth60
3 independent publishersCompany relevance100
share tied directly to this companyFreshness9
recency-weighted evidenceAgreement98
how closely stories agreePublisher mix37
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 11.7+4.7%
02 Oct 202649USD 11.17+4.8%
25 Sep 202648USD 10.66+0.6%
18 Sep 202649USD 10.6-0.2%
11 Sep 202652USD 10.62-6.7%
04 Sep 202653USD 11.385+5.1%
28 Aug 202652USD 10.83+10.7%
21 Aug 202650USD 9.78+5.8%
Provisional evidence
News subjects
What is shaping the score
Market update506 stories · 40%
Earnings464 stories · 27%
Analyst action504 stories · 27%
Guidance501 stories · 7%
Source mix
Where the evidence comes from
AD HOC NEWS433 stories · 20%
MarketBeat442 stories · 13%
Business Wire502 stories · 13%
Stock Titan502 stories · 13%
Investing.com Canada501 stories · 7%
The Globe and Mail501 stories · 7%
Investing.com501 stories · 7%
Recurring subjects
Subjects appearing most often
Life Sciences9Financial Markets6Earnings6Finance3
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
04 Jul50 neutral16 Oct 15:15
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 16 Oct 15:15 | 50 | +0 | 15/100 (-1) | 15 (-1) | Provisional |
| 07 Oct 23:59 | 50 | +0 | 16/100 (-1) | 16 (+1) | Provisional |
| 06 Oct 23:59 | 50 | +0 | 17/100 (0) | 15 (0) | Provisional |
| 05 Oct 23:59 | 50 | +1 | 17/100 (-2) | 15 (0) | Provisional |
| 02 Oct 23:59 | 49 | +0 | 19/100 (0) | 15 (-2) | Provisional |
| 01 Oct 23:59 | 49 | +0 | 19/100 (-1) | 17 (+2) | Provisional |
| 30 Sep 23:59 | 49 | +0 | 20/100 (-1) | 15 (0) | Provisional |
| 29 Sep 23:59 | 49 | +0 | 21/100 (-1) | 15 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 15 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings2 stories
100.0%0.0%
Market update1 story
0.0%0.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
75.3%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 07 Oct 2026 12:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Raymond James reiterates USD 19.00 target for Vir Biotechnology stock
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 06 Oct 2026 03:31
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 20:05
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Vir Biotechnology to present hepatitis delta trial data at AASLD By Investing.com
Vir Biotechnology, Inc. (NASDAQ:VIR) announced it will present data from its Phase 2 SOLSTICE trial at the American Association for the Study of Liver Diseases meeting. The company will deliver two oral presentations on November 8, 2026, focusing on the efficacy of elebsiran and tobevibar…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Vir Biotechnology, Inc. (NASDAQ:VIR) announced it will present data from its Phase 2 SOLSTICE trial at the American Association for the Study of Liver Diseases meeting. The company will deliver two oral presentations on November 8, 2026, focusing on the efficacy of elebsiran and tobevibart combination treatment for chronic hepatitis delta infection and intrahepatic NK cell changes. Chronic hepatitis delta is the most severe form of chronic viral hepatitis, with limited approved treatments.
- Published
- 05 Oct 2026 19:59
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Vir Biotechnology Appoints Aziz Sawaf as New CFO
Vir Biotechnology announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf, previously of Theravance Biopharma and Gilead Sciences, will receive a $520,000 base salary, performance-linked bonuses, and significant sto…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Vir Biotechnology announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf, previously of Theravance Biopharma and Gilead Sciences, will receive a $520,000 base salary, performance-linked bonuses, and significant stock grants. This move is seen as an effort to strengthen Vir's financial leadership as it advances its cancer immunotherapy and hepatitis delta virus programs.
- Published
- 02 Oct 2026 13:12
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Vir Biotechnology names Aziz Sawaf as chief financial officer
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective Sunday. Sawaf will oversee the company's finance, IT, and investor relations functions, bringing over 20 years of biopharmaceutical experience. He joins from …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Vir Biotechnology, Inc. announced the appointment of Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective Sunday. Sawaf will oversee the company's finance, IT, and investor relations functions, bringing over 20 years of biopharmaceutical experience. He joins from Theravance Biopharma, Inc., where he served as CFO.
- Published
- 01 Oct 2026 22:04
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO.
Vir Biotechnology (VIR) has appointed Aziz Sawaf as its new Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will receive an annual base salary of $520,000, a target annual bonus of 45% of his base salary, and a $150,000 sign-on bonus paid in two inst…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Vir Biotechnology (VIR) has appointed Aziz Sawaf as its new Executive Vice President and Chief Financial Officer, effective October 5, 2026. Sawaf will receive an annual base salary of $520,000, a target annual bonus of 45% of his base salary, and a $150,000 sign-on bonus paid in two installments, contingent on continued employment. He will also be granted options for 150,000 shares and 75,000 restricted stock units, vesting over four years.
- Published
- 01 Oct 2026 13:02
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Analyst actionNot used in direction
Raymond James reiterates USD 19.00 target for Vir Biotechnology stock
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 10:00
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Sell-side brokerages have given Vir Biotechnology, Inc. (NASDAQ:VIR) a "Moderate Buy" rating, with an average 12-month price target of $21.57, significantly higher than its current share price of $10.65. Institutional investors own a substantial 65.32% of the company, and Vir recently sur…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Sell-side brokerages have given Vir Biotechnology, Inc. (NASDAQ:VIR) a "Moderate Buy" rating, with an average 12-month price target of $21.57, significantly higher than its current share price of $10.65. Institutional investors own a substantial 65.32% of the company, and Vir recently surpassed earnings per share and revenue estimates in its latest quarterly report. However, the company reported a negative net margin and return on equity, and analysts project a negative EPS for the current year.
- Published
- 30 Sep 2026 08:21
- News subject
- Analyst action
- Why this score
- Beat expectations
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout
Vir Biotechnology (NASDAQ:VIR) is nearing a significant data readout for its ECLIPSE program targeting chronic hepatitis delta, with the first study's topline results expected in Q4 and subsequent studies in Q1 next year. The company's financial position is strong, with over one billion d…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Vir Biotechnology (NASDAQ:VIR) is nearing a significant data readout for its ECLIPSE program targeting chronic hepatitis delta, with the first study's topline results expected in Q4 and subsequent studies in Q1 next year. The company's financial position is strong, with over one billion dollars in cash, extending its operating runway into H2 2028. Hepatitis delta is a severe form of chronic viral hepatitis with limited treatment options, highlighting the urgent medical need Vir Biotechnology aims to address.
- Published
- 29 Sep 2026 17:23
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
GuidanceNot used in direction
Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 07:00
- News subject
- Guidance
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
38/100 tone
Vir Biotechnology stock fell 3.34 percent to USD 10.72 after reporting strong Q2 2026 revenue of USD 238.9 million, largely due to a USD 240 million Astellas upfront payment. Despite the revenue beat and a shift from a net loss to a net income, the stock declined in after-hours trading. T…
75.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Vir Biotechnology stock fell 3.34 percent to USD 10.72 after reporting strong Q2 2026 revenue of USD 238.9 million, largely due to a USD 240 million Astellas upfront payment. Despite the revenue beat and a shift from a net loss to a net income, the stock declined in after-hours trading. The company's future valuation hinges on upcoming clinical trial data, with analyst Patrick Trucchio maintaining a Buy rating and a USD 20 price target.
- Published
- 25 Sep 2026 08:21
- News subject
- Earnings
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 75.3% of directional evidence · 21.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
42/100 tone
Engineers Gate Manager LP significantly reduced its stake in Vir Biotechnology (NASDAQ:VIR) by selling 121,964 shares, though institutional ownership remains high. Despite the sale, analyst sentiment for Vir Biotechnology is generally positive, with a "Moderate Buy" consensus and an avera…
24.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Engineers Gate Manager LP significantly reduced its stake in Vir Biotechnology (NASDAQ:VIR) by selling 121,964 shares, though institutional ownership remains high. Despite the sale, analyst sentiment for Vir Biotechnology is generally positive, with a "Moderate Buy" consensus and an average price target significantly above its current trading price. The company also surpassed its recent quarterly earnings and revenue estimates.
- Published
- 19 Sep 2026 02:16
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 24.7% of directional evidence · 27.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
42/100 tone
A former officer of Vir Biotechnology, Jason V. O'Byrne, has filed a Rule 144 notice indicating planned sales of common stock. The filing details recent sales, including 28,333 shares sold for $315,241.46 on September 9, 2026, and outlines future sales from restricted stock vesting and ES…
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
A former officer of Vir Biotechnology, Jason V. O'Byrne, has filed a Rule 144 notice indicating planned sales of common stock. The filing details recent sales, including 28,333 shares sold for $315,241.46 on September 9, 2026, and outlines future sales from restricted stock vesting and ESPP purchases between late 2025 and mid-2026. This notice is a regulatory requirement for insiders selling restricted securities.
- Published
- 17 Sep 2026 20:49
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- <0.1% of directional evidence · 28.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
Behavioral Patterns of VIR and Institutional Flows
This article analyzes Vir Biotechnology Inc. (NYSE: VIR) using AI models, identifying a weak near-term sentiment despite long-term strength. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article analyzes Vir Biotechnology Inc. (NYSE: VIR) using AI models, identifying a weak near-term sentiment despite long-term strength. It presents three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and key support and resistance levels for VIR.
- Published
- 17 Sep 2026 00:02
- News subject
- Analyst action
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
Earlier company news
VIR news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 76 older VIR headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to VIR, but the headline and available text are not mainly about Vir Biotechnology Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of VIR sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.